MBMariia Bocharova

Mariia Bocharova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mariia Bocharova has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Late-onset depression predicts cognitive impairment and subsequent dementia among older adults with major depressive disorder: findings from UK Biobank and primary care linked data

    by Lingfeng Xue, Mariia Bocharova, Allan H. Young, Dag Aarsland

    Background: Late-life depression (LLD) is associated with cognitive impairment and an elevated risk of dementia, yet the influence of age at depression onset on cognitive prognosis remains unclear. Emerging evidence suggests that late-onset depression, defined as first depressive episode in later adulthood, may reflect distinct neuropathological mechanisms and predict more severe cognitive decline and greater dementia risk than early-onset depression. Aims: This study aimed to investigate whether late-onset depression is linked to domain-specific cognitive impairment and higher risk of incident dementia among older adults with major depressive disorder. Method: We analysed UK Biobank data from older adults (aged ≥60 years) with primary care linkage, classifying participants into depression-free controls, early-life depression, late-life depression with early onset (LLD-EO) and late-life depression with late onset (LLD-LO). Cognitive performance across these five domains was assessed cross-sectionally at baseline using touchscreen tasks. Incident dementia was evaluated prospectively using clinical records up to 2022. Multi-level models with inverse-probability weighting and survey-adjusted mixed modelling were applied to assess group differences in cognitive function, controlling for demographic covariates, lifestyle factors and physical and mental health conditions. A Cox regression model was employed to estimate dementia risk among groups. Results: Among 75 064 participants aged ≥60 years, the LLD-LO group ( n = 4858) showed significantly worse cognitive performance than healthy controls, particularly on fluid intelligence and visuospatial memory. The LLD-LO group performed worse than LLD-EO on fluid intelligence. During follow-up, LLD-LO was associated with a higher risk of incident dementia (hazard ratio 1.42–1.52) across all adjusted models. Deficits in fluid intelligence and visuospatial memory partially mediated the link between LLD-LO and subsequent dementia. Conclusions: Late-onset depression showed more severe impairment in fluid intelligence compared with LLD-EO. Late-onset depression was associated with increased incident dementia compared with depression-free individuals.


  • Open Access

    Late-life affective disorders and risk of progression to dementia: retrospective cohort study of patients in secondary care

    by Laith Alexander, Katherine Beck, Mariia Bocharova, Allan H. Young, Robert Stewart, Rowena Carter, Christoph Mueller

    Background: Late-life affective disorders (LLADs) are common and are projected to increase by 2050. There have been several studies linking late-life depression to an increased risk of dementia, but it is unclear if bipolar affective disorder or anxiety disorders pose a similar risk. Aims: We aimed to compare the risk of LLADs progressing to all-cause dementia, and the demographic and clinical variables mediating the risk. Methods: We used the South London and Maudsley National Health Service Foundation Trust Clinical Records Interactive Search system to identify patients aged 60 years or older with a diagnosis of any affective disorder. Cox proportional hazard models were used to determine differences in dementia risk between late-life anxiety disorders versus late-life depression, and late-life bipolar disorder versus late-life depression. Demographic and clinical characteristics associated with the risk of dementia were investigated. Results: Some 5695 patients were identified and included in the final analysis. Of these, 388 had a diagnosis of bipolar affective disorder, 1365 had a diagnosis of an anxiety disorder and 3942 had a diagnosis of a depressive disorder. Bipolar affective disorder was associated with a lower hazard of developing dementia compared to depression (adjusted model including demographics and baseline cognition, hazard ratio: 0.60; 95% CI: 0.41–0.87). Anxiety disorders had a similar hazard of developing dementia (adjusted hazard ratio: 1.05; 95% CI: 0.90–1.22). A prior history of a depressive disorder reduced the risk of late-life depression progressing to dementia – suggesting the new onset of a depressive disorder in later life is associated with higher risk – but a prior history of anxiety disorders or bipolar affective disorder did not alter risk. Conclusions: LLADs have a differential risk of developing all-cause dementia, with demographic- and illness-related factors influencing the risk. Further prospective cohort studies are needed to explore the link between LLADs and dementia development, and mediators of the lower risk of dementia associated with late-life bipolar disorder compared to late-life depression.


  • Open Access

    The role of plasma inflammatory markers in late-life depression and conversion to dementia: a 3-year follow-up study

    by M. Bocharova, T. Borza, L. O. Watne, K. Engedal, J. T. O’bRien, G. Selbæk, A. V. Idland, J. Hodsoll, A. H. Young, D. Aarsland

    Late-life depression (LLD) has been linked to increased likelihood of dementia, although mechanisms responsible for this association remain largely unknown. One feature frequently observed in both LLD and dementia is elevated levels of plasma inflammatory markers. The present study aimed to compare the levels of 12 plasma inflammatory markers between older people with LLD and controls, and to explore whether these markers, along with clinical characteristics, can predict dementia in patients with LLD within 3 years of follow-up. Using multiple linear regression with stepwise adjustment, we compared levels of plasma inflammatory markers (IL-1β, IL-1ra, IL-6, IL-10, IL-17a, IL-18, IL-33, TNFα, CD40L, IFN-γ, CCL-2 and CCL-4) between 136 inpatients with LLD (PRODE cohort) and 103 cognitively healthy non-depressed controls (COGNORM cohort). In the PRODE cohort, follow-up data was available for 139 patients (of them 123 had data on baseline plasma inflammatory markers); 36 (25.9%) developed dementia by Year 3 (n = 31 for those with cytokine data). Using Cox proportional hazards regression, we explored whether inflammatory markers and clinical characteristics of LLD (age of onset, treatment response, number of episodes) predicted progression to dementia during follow-up. Levels of IL-1ra, CCL-2, CCL-4, IFN-γ and IL-17a were significantly higher in LLD patients compared to controls in the majority of models. However, none of the inflammatory markers predicted progression from LLD to dementia in the PRODE cohort. Among clinical features, only poor response to treatment significantly predicted higher risk of progression to dementia.


  • Open Access

    Anhedonia in the structure of post-COVID syndrome in psychiatric inpatients: the probable role of obesity, systemic inflammation, vascular disregulation and general therapeutic comorbidity

    by N. B. Lutova, N.. G. Neznanov, A. V. Shabelnik, E. S. Gerasimchuk, M. O. Bocharova, M. Yu. Sorokin

    COVID-19 caused not only acute but also delayed neuropsychiatric disorders. A highly probable manifestation of the latter may be physical anhedonia, since this transnosological psychopathological phenomenon is associated with a violation of metabolic and neuroinflammatory processes. The goal. To identify the prevalence of physical anhedonia in the clinic of post-COVID syndrome and to assess the association of this transnosological psychopathological symptom with concomitant somatic burden, the severity of the SARS-CoV-2 infection and the time elapsed since the disease. Materials and Methods. The prevalence of acute and delayed neuropsychiatric symptoms was assessed in 48 psychiatric inpatients with severe mental disorders depending on the history of COVID-19. Quantitative and qualitative assessment was carried out by self-reporting on the number of simultaneously present groups of chronic diseases, and the severity of obesity was objectively assessed - by body mass index, dysregulation of vascular tone-by blood pressure variability, systemic inflammation - by sed rate and platelet-lymphocyte ratio (PLR). Physical anhedonia was detected using the Russian-language version of the Revised physical anhedonia scale (RPAS). Results. The association between the severity of COVID-19 and the severity of anhedonia, as a probable component of post-COVID syndrome, was confirmed. The total general therapeutic burden was the most important predictor of acute and delayed neuropsychiatric symptoms against the background of COVID-19. The probable role of metabolic syndrome, systemic inflammation and vascular tone was shown in the development of late disorders after coronavirus infection. Conclusion. The role of general therapeutic burden (including obesity, vascular dysregulation and systemic inflammation) in the development of anhedonia in patients with mental disorders who have had COVID-19 has been demonstrated.


  • Open Access

    Neuroimaging markers of phenomena of perceived stigmatization in people with and without mental disorders: a systematic scoping-review

    by Natalia B. Lutova, Maria A. Khobeysh, Ekaterina S. Gerasimchuk, Maria O. Bocharova, Olga V. Makarevich, Mikhail Yu. Sorokin, М. А. Хобейш

    Summary. Along with traditional research on psychiatric stigma, there has recently been increasing interest in the neurobiological factors associated with stigmatization.Aim: to study the most common research methods in the studies of the neurobiological correlates of stigmatization phenomenon and its components, as well as to systematize their results, taking into account their methodological limitations.Materials and Methods: The review was conducted in accordance with the PRISMA-ScR extension. Studies were searched in MEDLINE, EMBASE, PsycINFO using the Ovid platform. After evaluating 2358 articles according to inclusion, non-inclusion, and exclusion criteria, 20 articles were included in the final analysis.Results: The most of the studies were conducted on samples of healthy respondents without a control group (14 articles). The mean age of respondents ranged from 18.8 [1.0] to 42.7 [14.7] years. Psychiatric stigma was studied in 2 studies; in the remaining articles, various components of stigma were studied, among which social rejection sensitivity was most often studied (13 articles). Among fMRI paradigm the Cyberball social exclusion task was used more often (10 articles). Changes in neural activity, correlating with the severity of stigma and its constituent constructs, were found in the anterior cingulate cortex, prefrontal cortex, insula, thalamus, hypothalamus, hippocampus, parahippocampal gyrus, ventral region of the striatum, putamen, amygdala.Conclusion: Functional magnetic resonance studies can be an effective tool for verifying and assessing the dynamics of the psychological state of people experiencing the phenomenon of stigmatization.

  • Open Access

    Assessing Neutrophil-to-Lymphocyte Ratio as a Nutritional Indicator in Community-Dwelling Older Adults

    by Miguel Germán Borda, Pablo Lafuente Sanchis, Jonathan Patricio Baldera, Francisco José Tarazona-Santabalbina, Diego Andrés Chavarro-Carvajal, Salomón Salazar-Londoño, Mariia Bocharova, Dag Aarsland, Antonio Martín-Marco


  • Open Access

    Psychopharmacotherapy factor in the variants of COVID-19 course in psychiatric inpatients

    by N. G. Neznanov, O. V. Limankin, A. V. Shabelnik, L. A. Azarova, N. B. Lutova, M. O. Bocharova, M. Yu. Sorokin

    The aim of this study is to examine the relationship between the severity and duration criteria of COVID-19 and the psychopharmacotherapy administered to patients in within a psychiatric hospital.Materials and Methods. We analyzed 169 case histories involving completed clinical cases of COVID-19 treatment in a specialized infectious psychiatric department in St. Petersburg, covering the period from May 2020 to January 2021. Correlation, dispersion, and regression analyses were employed to evaluate severe and mild COVID-19 progression indicators, as well as the duration of persistent SARS-CoV-2 viral shedding. We assessed the clinical and laboratory parameters in patients, along with the psychopharmacotherapy administered, including antidepressants, antipsychotics, and acid sphingomyelinase inhibitors (FIASMA-active drugs).Results. Cardiovascular diseases emerged as a predictor of severe COVID-19 when combined with an increasing platelet-to-lymphocyte ratio (PLR), increasing the risk of severe course by over two-fold. The use of any psychotropic agents was associated with a 0.9% increase in the risk of severe course of COVID-19 for each unit increase in the systemic inflammation index PLR, specifically in patients with intellectual disability (ICD-10 codes F70-79), when compared to patients with schizophrenia (ICD-10 codes F20-29). High PLR values and the use of FIASMA-active drugs were associated with prolonged COVID-19 duration, while antidepressant therapy and elevated C-reactive protein levels were associated with a reduced predicted duration of viral shedding in 13.8% of variance. Additional consideration of the nosology of psychiatric disorders in the regression model increased the proportion of explained variance to 22.8%.Conclusion. Consideration should be given to thymoanaleptic therapy for individuals with psychiatric disorders during periods of increased disease incidence leading up to potential SARS-CoV-2 infection, as it may serve as a protective factor against COVID-19. Furthermore, there is no evidence to suggest adverse effects of antipsychotics on the severity and duration of COVID-19. Further research is required to investigate the effects of FIASMA-active psychopharmacological agents within nosologically homogeneous groups.


  • Adaptation and validation of the Physical Anhedonia Scale (Revised Physical Anhedonia Scale): psychometric properties of the Russian-speaking methodology

    by N.B. Lutova, M.A. Khobeysh, O.V. Makarevich, M.O. Bocharova, E.S. Gerasimchuk, M.YU. Sorokin

    The phenomenon of anhedonia, reflecting a decrease in the ability to experience pleasure from subjectively pleasant everyday aspects of life, is of high importance for mental health, being part of the symptoms of chronic mental and somatic diseases. Despite the popularity and widespread use of various methods for assessing anhedonia, adaption and validation procedures for the physical anhedonia scale in the Russian-speaking sample have not been yet carried out. Objective: adaptation and validation of the Revised Physical Anhedonia Scale (RPAS, Chapman L.J., Chapman J.P., 1970-1980) on a Russian-speaking sample of respondents. The total sample of 907 people: 1) "population group" – the online survey respondents – 710 (78.3%); 2) "inpatient patients" – 197 (21.7%) – with diagnoses F2, F3, F0, F4 and F6 (ICD-10). The translation of the original questionnaire (RPAS) into Russian and its language adaptation, assessment of internal and external validity – convergent (with the Social Anhedonia Assessment Scale (RSAS)) and discriminant (with the Adverse Childhood Experience Questionnaire (ACEQ)) were carried out. The average total RPAS score (N = 907) was M(SD) = 15.3 (9.413), Me = 13 (IQR 8-20). The Cronbach's α for the total sample was 0.90; KMO = 0.88; Bartlett test – p <0.001. Alternative models were considered in the exploratory factor analyses results: with 1, 2, 3, 12 factors. The singlefactor model turned out to be the most stable (27% of the variance). Its’ confirmatory factor analyses (56 points) was performed: AIC = 21174.3, BIC = 21635.3, CFI = 0.566, TLI = 0.556, RMSEA = 0.061 (0,50…0,63). ROC analysis: the optimal threshold level for maximum discrimination was 18.5 points, sensitivity – 75.98%, and specificity – 48.72%. Сonvergent (RSAS; rho = 0.474; p <0.001), and discriminant (ACEQ; rho = 0.154; p = 0.207) validity was confirmed. Despite certain limitations of the proposed model, based on the experience of foreign studies, considering RPAS as a unidimensional scale evaluating the multifactorial phenomenon of physical anhedonia seems preferable. At the same time, the complexity of the studied construct requires continued research. The results of the study indicate satisfactory psychometric properties of the Russian-language version of RPAS, which makes it possible to use it for a Russian-language sample.


  • Transcultural Validity of Concept of Internalized Stigma in Patients with Mental Illnesses (Psychometric Properties of Russian Version of Internalized Stigma of Mental Illness Scale)

    by Mariya O. Bocharova, Kirill F. Vasil'CHenko, Nataliya B. Lutova, Ol'GA V. Makarevich, Mariya A. Khobeysh, Mikhail Yu. Sorokin, Ekaterina S. Gerasimchuk, Хобейш Мария Александровна

    INTRODUCTION: One of the commonest methods of evaluation of internalized stigma is Internalized Stigma of Mental Illness (ISMI) scale where the differences in the prevalence and perception of mental stigma in different cultures are specified. AIM: Validation of Russian version of ISMI scale and evaluation of peculiarities of perception of stigma by Russian-speaking patients with severe psychiatric disorders. MATERIALS AND METHODS: Four hundred thirty nine patients with severe psychiatric disorders (F2 and F3 according to the International Statistical Classification of Diseases and Related Health Problems, 10th revision) were examined. The psychometric properties of the Russian version of ISMI scale were evaluated using internal consistency analysis. Exploratory and confirmatory factor analysis (EFA and CFA, respectively) were performed. To check age- and gender-related invariance, MIMIC and MIFA models were used, and discriminative power and accuracy of scoring were identified using generalized partial credit model (GPCM). The results of EFA were compared with the data obtained in the Regional Clinical Hospital (n = 120) using independent alternative version of ISMI translation into Russian. RESULTS: The internal consistency of the Russian version of ISMI questionnaire was high: Chronbachs 0.90. EFA permitted to identify 4 factors. The first factor (Demoralization, F1) combined elements corresponding to subscale 1 (Alienation) and subscale 2 (Social withdrawal) of the original version of ISMI questionnaire. The other three factors identified in this study according to the content of the items, corresponded to the remaining subscales of the original ISMI scale. In all kinds of the conducted analysis, item 14 had low factor weight. CFA confirmed the four-factor structure. In the sample, MIMIC and MIFA showed the general age- and gender-related invariance with their insufficient power. GPCM showed good characteristics of discriminative power and difficulties in choice of scoring for all factors except the fourth one (Resistance to stigma). EFA performed on the data of the alternative sample, neither could reliably reproduce the five-factor structure of the original ISMI scale due to eclectic mixing of the items of the original scale within five isolated structures. CONCLUSION: The suitability of using the internalized stigma assessment tool for the Russian-speaking population has been confirmed. The study highlights the relevance and necessity of expanding transcultural studies of psychological reactions of psychiatric patients.


  • Open Access

    Computational psychiatry approach to stigma subtyping in patients with mental disorders: explicit and implicit internalized stigma

    by Mikhail Yurievich Sorokin, Natalia Borisovna Lutova, Maria Olegovna Bocharova, Maria Alexandrovna Khobeysh, Victor Davidovich Wied, Хобейш Мария Александровна, Вид Виктор Давыдович

    BACKGROUND: Psychiatric stigma has potentially controversial effects on patients health-related behaviors. It appears that both stigmatization and motivation in psychiatric patients are heterogeneous and multi-dimensional, and that the relationship between stigma and treatment motivation may be more complex than previously believed. AIM: To determine psychiatric stigma subtypes as they relate to treatment motivation among inpatients with various mental disorders. METHODS: Sixy-three psychiatric inpatients were examined by the Treatment Motivation Assessment Questionnaire (TMAQ) and the Russian version of Internalized Stigma of Mental Illness scale (ISMI). K-Means cluster and dispersion analysis were conducted. RESULTS: Cluster 3 (25 subjects) was the least stigmatized. Cluster 1 (18 subjects) showed an explicit stigma. Cluster 2 (20 subjects) showed an implicit stigma that took the form of the lowest treatment motivation compared to other clusters. Implicitly stigmatized patients, in contrast to explicitly stigmatized individuals, showed a decline in 3 out of 4 TMAQ factors (Mean dif.=1.051.67). CONCLUSION: Cooperation with doctors, together with reliance on ones own knowledge and skills to cope with the disorder, might be the way to overcome an internalized stigma for patients with mental disorders.